Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Simcere Enters Co-development Partnership With San Francisco Biotech Outfit On Monoclonal Antibody Treatment, Scans China For Takeover Targets

This article was originally published in PharmAsia News

Executive Summary

BEIJING - While reporting a strong rise in earnings for 2008, the leaders of China's Simcere Pharmaceutical Group said they have signed a co-development deal with a San Francisco biotech firm on a monoclonal antibody treatment for cancer
Advertisement

Related Content

Chinese Pharma Simcere Files IND For Humanized Rabbit Monoclonal Antibody
Chinese Pharma Simcere Files IND For Humanized Rabbit Monoclonal Antibody
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
China's Leading Drug Outfits Gear Up To Push Development Of Biologics, Biosimilars
Simcere's Endu Becomes First Drug To Complete Phase IV Trials Under New Drug Registration Regs
China's Simcere Signs Novel Licensing Agreement Covering U.S.-based OSI Pharmaceutical's Cancer Drug
While Cementing Partnership With U.S. Biotech Firm, Cash-rich Simcere Launches Twin Acquisitions Targeting Biosimilar, Vaccine Outfits In China
Magnitude 7.9 Quake Cut into Simcere Pharmaceutical’s First-half Earnings; Company “Very Close” To First Round Of Acquistions
Magnitude 7.9 Quake Cut into Simcere Pharmaceutical’s First-half Earnings; Company “Very Close” To First Round Of Acquistions
CFO of China’s Simcere Sees Year of Acquisitions For 2008 - PharmAsia News Spotlight
Advertisement
UsernamePublicRestriction

Register

SC071024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel